ANL (Adlai Nortye) Buyback Yield %: 0.00 (As of Jul. 09, 2026)


What is Adlai Nortye Buyback Yield %?

Adlai Nortye ANL +4.22% Buyback Yield % is 0.00 as of Jul. 09, 2026. The stock has 7 warning signs investors should review. Among 741 Biotechnology companies, Adlai Nortye ranks worse than 134952.63% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Adlai Nortye's current buyback yield was 0.00%.

Adlai Nortye Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Buyback Yield % Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 -27.67 0.00 0.00

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only -27.67 0.00 0.00 0.00 0.00

ANL vs OMER, PRME, DNA: Buyback Yield % Comparison

For the Biotechnology subindustry, Adlai Nortye's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Buyback Yield % falls into.


Adlai Nortye Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Adlai Nortye's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 56.8
=0.00%

Adlai Nortye's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 56.8
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Adlai Nortye (ANL) has a Buyback Yield % of 0.00 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #999999 out of 741 companies in the Biotechnology industry.
Is Adlai Nortye's Buyback Yield % too high?
Adlai Nortye's current Buyback Yield % is 0.00. Based on the distribution chart, Adlai Nortye ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's Buyback Yield % compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #999999 out of 741 companies for Buyback Yield %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Buyback Yield % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.